Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: A randomized, double-blind, clinical trial

Diabetes, Obesity and Metabolism

Volumn 8, Issue 2, 2006, Pages 197-205

  Derosa, Giuseppe ^a   Gaddi, A V ^b   Piccinni, M N ^a   Salvadeo, S ^a   Ciccarelli, L ^a   Fogari, E ^a   Ghelfi, M ^a   Ferrari, I ^a   Cicero, A F G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glimepiride; Metabolic syndrome; Metformin; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN BLOOD LEVEL; ITALY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33645979004     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00480.x     Document Type: Article

References (39)

1. Vague P. Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 2003; 29 (6 S): 5-7.
2. Johnson JA, Simpson SH, Majumdar SR, Toth EL. Decreased mortality associated with the use of metformin compared with sulphanylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 253: 854-865.
4. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
5. American Diabetes Association. American Diabetes Association: Clinical practice recommendations 2004. Diabetes Care 2004; 27 (1): S1-S147.
6. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003; 46 (1): 44-50.
7. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (6): 15-22.
8. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (3): S368-S376.
9. McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother 2001; 2 (4): 699-713.
10. Stumvoll M. Thiazolidinediones - some recent developments. Expert Opin Investig Drugs 2003; 12 (7): 1179-1187.
11. Camp HS. Thiazolidinediones in diabetes: Current status and future outlook. Curr Opin Investig Drugs 2003; 4 (4): 406-411.
12. Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52 (6): 1364-1370.
13. Abbink EJ, Pickkers P, Jansen van Rosendaal A et al. Vascular effects of glibenclamide vs. glimepiride and metformin in type 2 diabetic patients. Diabet Med 2002; 19 (2): 136-143.
14. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5 (3): 163-170.
15. National Cholesterol Education Program (NCEP) Expert Panel. Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
16. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24 (1): S44-S47.
17. American Diabetes Association. Screening for diabetes (Position Statement). Diabetes Care 2001; 24 (1): S21-S24.
18. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of WHO Consultation. World Health Organ Tech Rep Ser 2000; 894: I-xii, 1-253.
19. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
20. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. Bunn HF, Gabbay HK, Gallop PM. The glycosylation of haemoglobin. Relevance to Diabetes Mellitus. Science 1978; 200: 21-27.
22. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
23. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
24. Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II). J Clin Chem Clin Biochem 1978; 15: 121-130.
25. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU ed. Methods of Enzymatic Analysis, 2nd English edn. New York: Academic Press, Inc, 1974; 18-31.
26. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
28. Leblond L, Marcel YL. The amphipathic a-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells. J Biol Chem 1991; 266: 6058-6067.
29. De Loof H, Rosseneu M, Yang C-Y et al. Human apolipoprotein: Analysis of internal repeats and homology with other apolipoproteins. J Lipid Res 1987; 28: 1455-1465.
30. Winer BJ. Statistical principles in experimental design, 2nd edn. New York: McGraw-Hill, 1971.
31. Despres JP. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes Metab 2003; 29 (6 S): 53-61.
32. Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16 (8): 617-622.
33. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5 (3): 163-170.
34. Virtanen KA, Hallsten K, Parkkola R et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52 (2): 283-290.
35. Hallsten K, Virtanen KA, Lonnqvist F et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 2002; 51 (12): 3479-3485.
36. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25 (2): 472-484.
37. Derosa G, Cicero AFG, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26 (5): 744-754.
38. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18 (2): 127-134.
39. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-1405.